# Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

> **NCT06616584** · PHASE2,PHASE3 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 378 (estimated)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Cemiplimab
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dexamethasone
- **DRUG:** Docetaxel
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT06616584
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616584, "Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06616584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*